OXURION
Live / Registered — Cancelled — Section 71 (as of 26 Dec 2025)
What this means for you
Registered since 11 Jun 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79239267
- Registration number
- 5772180
- Mark type
- Stylized text
- Filed
- 25 Jun 2018
- Published for opposition
- 26 Mar 2019
- Registered
- 11 Jun 2019
- Attorney of record
- Martin W. Schiffmiller
Goods and services
- Class 005 — Pharmaceuticals: Biopharmaceutical preparations for use in the treatment of hypertension, strokes, cardiac diseases and vascular diseases; diagnostic medical reagents, chemicals preparations and biological materials all the foregoing being in the form of spatially defined arrays and solutions and reagents for medical laboratory use in diagnosting, monitoring, and predicting diseases and for measuring and predicting response to therapy of cardiac and vascular diseases; pharmaceutical preparations for use in the treatment of hypertension, strokes, cardiac diseases and vascular diseases; pharmaceutical substances and medicines for treatment or prevention of eye disorders and diseases and of ophthalmological disorders and diseases; pharmaceutical preparations and substances for the treatment or prevention of diabetes; medicines for treating or preventing diabetes; ophthalmic medicines and surgical fluids, ophthalmic pharmaceutical preparations; pharmaceutical eye drops
- Class 042 — Scientific and technological services: Scientific and technological services, namely research and design relating thereto in the field of ophthalmology, in the field of diabetes and in the field of treatment of cardiovascular disease, cardiac disease and vascular disease; industrial analysis of the pharmaceutical preparations of others used for the treatment of ophthalmologic diseases, diabetes and cardiovascular diseases for quality control purposes; research services in the field of ophthalmology, diabetes and cardiovascular diseases; pharmaceutical and biopharmaceutical research and development; biopharmaceutical product evaluation; research in the field of treatment of cardiovascular disease, cardiac disease, and vascular disease; development of new treatments for pathologies in which vascular biology plays a critical role in the field of biopharmaceuticals
- Class 044 — Medical, beauty and agricultural services: Medical services; veterinary services; consultancy services, namely, consultancy in the medical, veterinary and pharmaceutical treatment of patients in the fields of ophthalmology, diabetes and cardiovascular diseases; medical services, namely, cardiac and vascular therapeutic, prognostic and diagnostic testing services
Owner
- Oxurion NV, BE
- ThromboGenics, BE
- ThromboGenics, BE
Prosecution history
- 26 Feb 2026 — NEW REPRESENTATIVE AT IB RECEIVED
- 26 Dec 2025 — CANCELLED SECTION 71
- 14 Nov 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 11 Jun 2024 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 12 Oct 2019 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 21 Sept 2019 — FINAL DISPOSITION NOTICE SENT TO IB
- 21 Sept 2019 — FINAL DISPOSITION PROCESSED
- 11 Sept 2019 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 13 Jun 2019 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 11 Jun 2019 — REGISTERED-PRINCIPAL REGISTER
- 26 Mar 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Mar 2019 — PUBLISHED FOR OPPOSITION
- 23 Mar 2019 — NOTIFICATION PROCESSED BY IB
- 06 Mar 2019 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 06 Mar 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED